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The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of
L-glutamate to L-arginine. Arginine auxotrophs (argB/argF deletion mutants) of Mycobacterium tubercu-
losis are rapidly sterilised in mice, while inhibition of ArgJ with Pranlukast was found to clear chronic
M. tuberculosis infection in a mouse model. Enzymes in the arginine biosynthetic pathway have therefore
emerged as promising targets for anti-tuberculosis drug discovery. In this work, the ligandability of four
enzymes of the pathway ArgB, ArgC, ArgD and ArgF is assessed using a fragment-based approach. We
identify several hits against these enzymes validated with biochemical and biophysical assays, as well
as X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activ-
ity against M. tuberculosis. These results demonstrate the potential for more enzymes in this pathway to
be targeted with dedicated drug discovery programmes.
 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
Despite the availability of effective chemotherapy, tuberculosis
(TB) remains a leading infectious cause of morbidity and mortality
worldwide. In 2019, an estimated 1.2 million deaths were caused
by TB, and an additional 208,000 were a result of HIV-TB co-
infection [1]. While the existing multidrug treatment regimen
has a success rate of 85% in drug-sensitive TB cases (in the 2018
cohort), drug toxicity, a long treatment duration leading to patient
non-compliance, as well as incompatibility with antiretroviral
therapy all compromise its effectiveness. Alarmingly, the emer-
gence of multi-drug resistant (MDR) andextensively-drug-resistant (XDR) strains ofMycobacterium tubercu-
losis has further undermined the efficacy of current antitubercular
therapy: only 57% of MDR cases were successfully treated world-
wide in the 2017 cohort. New antitubercular agents are therefore
urgently required and novel chemical scaffolds and mechanisms
of action must be identified that can shorten therapy and circum-
vent development of drug resistance. While many drugs currently
in clinical use are bacteriocidal, persister populations of metaboli-
cally heterogenous bacilli can form in the granuloma microenvi-
ronments and survive treatment due to acquired phenotypic
drug resistance [2]. Eliminating this persister reservoir will be cru-
cial for shortening treatment duration and preventing latent
forms/relapse of the disease. Future drug discovery campaigns
against M. tuberculosis could potentially address this by pursuing
targets that lead to rapid sterilisation of the bacilli inside the host.
M. tuberculosis, like Mycobacterium leprae, has retained its abil-
ity to synthesise all 20 amino acids and most vitamins. The reten-
tion of these biosynthetic genes reflects an evolutionary pressure,
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derive amino acids or many vitamins from the host and lead what
has thus been described as an autarkic lifestyle [3]. However, not
all amino acid auxotrophies behave the same. Several amino acid
auxotrophs have been found to have attenuated virulence inside
host organisms, suggesting that while enzymes in amino acid
biosynthetic pathways are essential in vitro, the pathogen can scav-
enge amino acids (albeit insufficiently) inside the host and survive
[4–10]. However, it was shown that methionine and arginine aux-
otrophs of M. tuberculosis are rapidly sterilised in both immuno-
competent and immunodeficient (SCID) mice without the
appearance of suppressor/bypass mutants [(3, 4]. Despite the
presence of two arginine transporters in M. tuberculosis [11,12]
and sufficiently high serum concentrations of arginine in the host
[13], the virulence of DargB or DargF mutants is entirely abolished
as arginine deprivation results in extensive oxidative damage [4].
The case for drug discovery approaches to target arginine biosyn-
thetic enzymes is further bolstered by work demonstrating that
chemical inhibition of ArgJ with Pranlukast, a cysteinyl leukotriene
receptor-1 antagonist use to treat asthmatic exacerbations, cleared
a chronicM. tuberculosis infection in BALB/c mice [14]. The arginine
biosynthesis pathway consists of eight different enzymes (Fig. 1A)
all considered to be essential for M. tuberculosis growth in vitro
[15]. Except for argA which encodes the first enzyme of the path-
way, all other genes are present in a single operon that also
includes the repressor argR (Fig. 1B).
Fragment based drug discovery (FBDD) is now an established
lead-generation strategy in both industry and academia, having
yielded over 30 compounds in clinical trials, including approved
cancer drugs like vemurafenib, Kisqali, Balversa and venetoclax
[16]. This approach consists of screening a library of small mole-
cules (150–300 Da) against a target of interest using biophysical,
biochemical and structural biology methods. The low complexity
of fragments allows for efficient exploration of the chemical space
of the target, often revealing unexpected binding sites in proteins.
Although fragments often bind weakly, they tend to bind toFig. 1. (a) The L-arginine biosynthesis pathway in Mycobacterium t
3492hotspot regions of the target, forming well defined interactions
that allow subsequent elaboration into larger drug-like molecules
[17,18]. Our group and a few others have pioneered using this
approach against different mycobacterial species and different pro-
tein targets with varying degrees of success [18–26].
Using this approach, we have screened four enzymes of the
arginine biosynthesis pathway that have not been explored by
drug discovery programmes: ArgB, ArgC, ArgD and ArgF. Herein
we report the structures of the four enzymes in complex with frag-
ment hits, including a novel allosteric site of ArgB and allosteric
inhibitors of this enzyme. Importantly, this work also assesses
the potential of these enzymes as candidates for future drug dis-
covery programmes.
2. Materials and methods
2.1. Molecular cloning
The argB gene was amplified from chromosomal DNA of M.
tuberculosis H37Rv strain obtained from ATCC (ATCC25618D-2)
while the ORFs of argC, argD and argF were purchased as E. coli
codon-optimised synthetic gene strings through the ThermoFisher
GeneArt Gene Synthesis service. The argB gene was cloned into
pHAT4 [27] using NcoI and XhoI sites. The gene strings of argC,
argD and argF were cloned into a pET28a vector (modified to
include an N-terminal 6xhis SUMO) [28] using BamHI and HindIII
restriction sites. All constructs were confirmed by sequencing.
2.2. Protein expression and purification
250 ml of autoclaved 2xYT broth (Formedium) prepared in dis-
tilled water, containing 100 lg/mL ampicillin for pHAT4:argB or
30 lg/mL kanamycin for pET28a:argC/argD/argF, was inoculated
with E. coli BL21(DE3) containing the respective expression con-
struct, and incubated at 37 C with 220 rpm shaking overnight.
This primary culture was used the following day to inoculate 6uberculosis. (b) M. tuberculosis L-arginine biosynthesis operon.
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the inoculated flasks were incubated under similar conditions until
the OD600nm reached 0.8–1. Overexpression was induced by the
addition of 0.5 mM isopropyl b-D-1-thiogalactopyranoside (IPTG).
Thereafter, the flasks were incubated at 20 C with 220 rpm shak-
ing overnight.
Cells were harvested by centrifugation at 4200 rpm, 4 C for
20 min in a Beckman Coulter ultracentrifuge. The cell pellets were
re-suspended in 50 ml of Buffer A (Table S1), also containing 1
tablet of cOmpleteTM, Mini, EDTA-free Protease Inhibitor Cocktail
(Roche, Merck), DNase I (Sigma-Aldrich) and 5 mMMgCl2. The cells
were lysed by ultrasonication for ~8 min (pulse on for 20 secs,
pulse off for 30 secs, 55% amplitude), the suspensions were kept
in an ice bath throughout. The cell lysates were clarified by cen-
trifugation (27000 g, 4 C for 40 min), and the supernatants were
syringe-filtered (0.45 lm membrane) to remove any cell debris.
The filtered lysates were subjected to IMAC using a His-Trap
5 ml Nickel column (GE Healthcare Life Sciences) on an ÄKTA Pure
system (GE Healthcare Life Sciences), equilibrated with buffer A
(Table S1). Isocratic elution was performed using buffer B
(Table S1). Proteins were dialysed in buffer C (Table S1) at 4 C
and tags were cleaved overnight by adding TEV protease for ArgB
or Ulp1 protease, for ArgC, ArgD and ArgF, both at 1:100 ratio.
The dialysed proteins were concentrated to a <5 ml volume
using a 30 kDa MWCO Vivaspin 20 centrifugal concentrator (Sarto-
rius) at 5000 g, 4 C and injected onto a HiLoad 16/600 Superdex
200 gel filtration column (GE Life Sciences) equilibrated with buf-
fer C (Table S1). Elution fractions corresponding to the peak of
interest in the chromatogram were pooled and fraction purity
was assessed by SDS-PAGE. The purest fractions of ArgB and ArgF
were pooled and concentrated to 20 mg.ml1. Pooled fractions of
ArgC were further dialysed into the final storage buffer (5 mM
Tris-HCl pH 7.4, 50 mM NaCl) overnight at 4 C, rescued the next
day and concentrated to 6.5 mg/mL. ArgD fractions were pooled
and aqueous pyridoxal-50-phosphate (PLP, Sigma-Aldrich) was
added (2 mM final PLP concentration). Overnight dialysis into the
storage buffer (50 mM Tris-HCl pH 7, 100 mM NaCl) was carried
out at 4 C to remove excess PLP. The PLP-saturated protein was
rescued the next day and concentrated to 14 mg/mL. The protein
yields were of 6.7, <1, <1 and 3.3 mg/L respectively for ArgB, ArgC,
ArgD and ArgF. All proteins were flash frozen in liquid N2 and
stored at 80 C.2.3. Differential scanning fluorimetry
Fragment screening was carried out in a 96-well PCR plate using
a CFX Connect Real-time PCR Detection System (Bio-Rad) for DSF.
For ArgB, each 25 lL reaction mixture contained 10 mM ArgB,
100 mM HEPES (pH 7.5), 200 mM NaCl, 5x SYPRO Orange, 5%
DMSO (v/v), and fragments at 5 mM. For ArgF each 25 lL reaction
mixture contained 5 mM ArgF, 25 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 5x SYPRO Orange dye, 5 mM fragments and 5% DMSO (v/v).
For ArgC and ArgD, the 25 lL reaction volume consisted of the fol-
lowing: 2.5 lM ArgC/5 lM ArgD, 100 mM sodium phosphate pH 7,
200 mM NaCl, 5x SYPRO Orange, and 5 mM fragments (960 frag-
ment library). The protocol implemented increased temperature
by 0.5 C after every 30 s, going from 25 C to 95 C and measuring
SYPRO Orange fluorescence for each temperature cycle. The melt
curve RFU (relative fluorescence units) and derivative -d(RFU)/dT
values were analysed and plotted using a macros-enabled Excel
Workbook: the minima of the melt curves were recorded as the
melting temperature (Tm) of the enzymes in the presence of each
fragment. The Tm of the reference control (protein in the presence
of DMSO) was subtracted from all the readings to calculate DTm.34932.4. Surface plasmon resonance
Low molecular weight (LMW) screening with the DSF fragment
hits was carried out using the T200 Biacore instrument (GE Health-
care Life Sciences). A series S CM5 sensor chip (GE Healthcare Life
Sciences) was used for the immobilisation of ArgC on the car-
boxymethylated dextran matrix through amine coupling. A
25 lg/mL ArgC dilution was prepared in the optimal coupling buf-
fer (sodium acetate pH 5), and immobilisation was performed by
manual instructions. The immobilised ArgC was tested using dilu-
tion series (19 lM to 2.5 mM) of NADP+ and NADPH. 50 mM frag-
ment DMSO stocks were used to prepare 1 mM dilutions in the SPR
buffer consisting of 10 mM sodium phosphate pH 7.0, 150 mM
NaCl and 2% DMSO (v/v). Each NADP+/NADPH and fragment dilu-
tion was injected once at a flow rate of 30 lL/min for a contact time
of 30 s, SPR Running buffer (10 mM sodium phosphate pH 7.0 and
150 mM NaCl) was passed for 320 s at the same flow rate, and 50%
DMSO v/v (diluted in SPR running buffer) was injected at the end of
the cycle to remove undissociated analyte. Solvent correction was
carried out to account for DMSO mismatch between the analyte
dilutions and the SPR running buffer.
A 30 lg/mL ArgD dilution was prepared in sodium acetate pH 4
buffer for immobilisation. Following the ethanolamine neutralisa-
tion step, 1 mM PLP (prepared in the SPR buffer) was injected for
a contact time of 420 s to ensure saturation of PLP-binding sites.
The immobilised ArgD was tested using dilution series (19 lM to
2.5 mM) of L-glutamate, N-acetylornithine and L-ornithine. Screen-
ing was also carried out against PLP-unsaturated ArgD.
2.5. Ligand-observed NMR
All NMR experiments were carried out at 25 C using a Bruker
Avance 600 MHz spectrometer with a Triple Resonance Inverse
(TCI) Automatic Tuning and Matching (ATM) cryoprobe. T2
relaxation-filtered one-dimensional NMR spectroscopy experi-
ments incorporated a CPMG67 spin-lock time of 200 ms before
the acquisition period. Samples (600 mL) containing 2 mM frag-
ment in the absence and presence of 10 mM ArgB were prepared
in buffer containing 20 mM potassium phosphate at pH 7.4 and
50 mM NaCl. Additionally, 2% d6-DMSO v/v was present in all sam-
ples for fragment solubilisation and field-frequency locking. Dis-
placement experiments were carried out in the same manner by
adding 1 mM each of ATP, and N-acetyl-L-glutamic acid or L-
arginine to the samples containing 2 mM fragment and 10 mM
ArgB. The samples were loaded into 5 mm NMR tubes (Wilmad,
526-PP) for measurement, and the resulting spectra were analysed
using TopSpin v. 3.5 (Bruker).
2.6. Crystallisation of the apoenzymes
Crystallisation screening and optimisation for all the enzymes
was performed at 18 C with the sitting drop vapour diffusion
method using a Mosquito robot (TTP-Labtech) to set up the crys-
tallisation experiments. For apo ArgB, 300 nL of pure protein at
10 mg.ml1 was mixed with an equal volume of reservoir solution
and equilibrated against 85 mL of the reservoir solution. The
selected condition was obtained in Wizards Classic 1&2 crystallisa-
tion screen (Rigaku), well G5 (1260 mM ammonium sulphate,
100 mM CHES pH 9.5 and 200 mM NaCl). Crystals appeared after
2 days in this condition and diffracted up to 1.8 Å resolution. For
ArgF, 200 nL of pure protein at 20 mg.ml1 was mixed with an
equal volume of reservoir solution. An initial crystallisation condi-
tion was identified I the Wizards Classic 3&4 crystallisation screen
(Rigaku), well F2 (40% PEG400, 100 mM Tris-HCl pH 7.5 and
200 mM Lithium sulphate). However, crystals obtained in this con-
dition contained two lattices with different orientations and no
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These crystals were ground to produce seeds and a new crystallisa-
tion screening was performed using 200 nL of ArgF at 20 mg.ml1
mixed with equal volume of reservoir solution and 50 nL of seed
solution. After several rounds of optimisation, the final crystallisa-
tion condition consisted of 150 mM ammonium dihydrogen phos-
phate and 10 mM praseodymium acetate. Crystals appeared after
2 days and diffracted up to 1.8 Å resolution.
A previously reported crystallisation condition for ArgC [29]
was reproduced with some modifications, but the crystals were
found to not be suitable for fragment soaking experiments. A
new crystallisation screen was therefore performed using 200 nL
of pure ArgC at 6.5 mg.ml1 mixed with an equal volume of reser-
voir solution. Well A8 from the BCS screen (Molecular Dimensions)
produced crystals diffracting to 1.54 Å. This condition consisted of
0.1 M phosphate/citrate buffer pH 5.5 and 20% PEG Smear High
(PEG 6 K, 8 K, 10 K) and was optimised to remove the cryoprotec-
tion step by adding 20% glycerol (v/v). A second condition with a
neutral pH, more amenable to soaking, based on the previous con-
dition was also optimised and consisted of 0.1 M Bis-Tris pH 7, 17%
PEG Smear High, 70 mM phosphate/citrate pH 5.6, 20% glycerol.
For ArgD, 200 nL of PLP-saturated enzyme 14 mg.ml1 was
mixed with an equal volume of reservoir solution. A condition
was found in PEG Smear BCS screen (Molecular Dimensions) well
F6 (0.1 M Bis-Tris Propane pH 8.5, 18% PEG Smear High (PEGs
6 K, 8 K, 10 K), 0.2 M Ammonium nitrate). The final optimised con-
dition consisted of 0.1 M Bis-Tris Propane pH 8.5, 18% PEG Smear
High, 0.2 M ammonium nitrate and 10 mM nickel chloride
(additive).
2.7. Crystal soaking and co-crystallisation with natural ligands and
fragment hits
To obtain ligand-bound structures, soaking was performed in
the crystallisation conditions described above for each protein
using the hanging drop vapour diffusion method.
For ArgB, 1.5 mL of protein storage buffer containing 20 mM of
ligand was mixed with 1.5 mL of reservoir solution, and drops were
left to equilibrate against 500 mL of reservoir solution for 3 days.
Crystals were then transferred to the drops and incubated for
16 h. A cryogenic solution was prepared by adding ethylene glycol
up to 27.5% (v/v) to the mother liquor. Crystals were briefly trans-
ferred to this solution, flash-frozen in liquid N2, and stored for data
collection. To obtain an ArgB-NAG complex, co-crystallisation with
2 mM NAG was performed instead. Crystals for ArgB-NAG complex
were obtained in Wizard Classic 1&2 screen (Rigaku), solution B6,
and were flash-frozen in liquid N2 after a brief soak in a solution
containing mother liquor and 27.5% ethylene glycol.
ArgC crystals grown in pH 5.5 were first soaked in 1.5 mL drops
containing the mother liquor and 5 mM NADP+ for 2 h in hanging
drops that were equilibrated against a reservoir of 500 mL. There-
after, the crystals were transferred to drops containing the crys-
tallisation condition and an SPR-validated fragments (20 mM,
10% DMSO), which were equilibrated against 500 mL of mother
liquor also containing a corresponding percentage of DMSO over-
night at 19 C. ArgC crystals grown in pH 7 were soaked with
5 mM NADP+ only for 5–10 min due to the rapid development of
cracks, and transferred to the fragment soaking drops for 5–
10 min from where they were fished and frozen.
ArgD crystals were soaked with fragments at a concentration of
50 mM overnight in otherwise the same manner as ArgC crystals
grown in pH 5.5. A cryogenic solution was prepared by adding
30% ethylene glycol to the mother liquor. Crystals were briefly
transferred to this solution and flash-frozen in liquid N2.
ArgF crystals were soaked in drops containing crystallisation
condition and 20 mM of ligand and equilibrated against 500 mL3494of reservoir solution for 16 h. A cryogenic solution was prepared
by adding 25% ethylene glycol to the mother liquor. Crystals were
briefly transferred to this solution and flash-frozen in liquid N2.
2.8. X-ray data collection and processing
X-ray diffraction data (single-wavelength anomalous diffrac-
tion) were collected on beamlines i02, i03, i04, i04-1 and i24 at
the Diamond Light Source (DLS), UK and on id30B at The European
Synchrotron Radiation Facility (ESRF). Diffraction data were pro-
cessed and reduced with autoPROC from Global Phasing Limited
[30] or Xia2 [31]. The apo-form of ArgB was crystallised in the
R32 space group with one protomer per asymmetric unit (ASU)
and the ArgB:NAG complex in the P63 space group with two pro-
tomers per ASU. ArgF was crystallized in the P21 space group with
6 protomers in the ASU. ArgC was crystallised in C2 and P21 space
groups, with 2 and 4/8 protomers per ASU respectively. ArgD was
crystallised in the P21 space group as well but with 4 protomers in
the ASU.
Initial phases were determined with PHASER [32] from PHENIX
software package [33] using the M. tuberculosis ArgB structure
(PDB: 2AP9), M. tuberculosis ArgF structure (PDB: 2P2G), M. tuber-
culosis ArgC structure (PDB: 2I3G) and E. coli Succinyl-ornithine
transaminase (AstC, 42% sequence identity, PDB: 4ADB) as a search
models, respectively for ArgB, ArgF, ArgC and ArgD. Model building
was done with Coot [34], and refinement was performed in PHE-
NIX [33,35] for ArgB, ArgF, and ArgC. For ArgD, after the initial
molecular replacement solution and a single cycle of refinement,
PHENIX AutoBuild was used to generate a model for M. tuberculosis
ArgD that was then refined with Coot and PHENIX. Structure vali-
dation was performed using Coot and PHENIX tools [33,34]. All fig-
ures were prepared with PyMOL (The PyMOL Molecular Graphics
System, Version 2.0 Schrodinger, LLC).
2.9. Isothermal titration calorimetry
The binding interaction between ArgB or ArgF and ligands was
characterised at 25 C, using a MicroCal ITC200 titration calorime-
ter (Microcal). An ArgB concentration between 75 and 150 mM was
used for all titrations. Ligands (0.75–2 mM) were injected in 1.5 mL
aliquots with a 150 s spacing between injections for compound 1
and 110 s spacing for all the others. For compound 2, L-
canavanine and L-arginine two titrations were concatenated. Titra-
tion data was recorded in 25 mM HEPES pH 7.4 with 200 mM NaCl.
Data were analysed by fitting a simple single-site model using Ori-
gin software (Microcal) (NMR711 and NMR446) or a six-site
sequential binding model (ArgB and L-canavanine).
ArgF was dialysed in 50 mM HEPES pH 8.0, 200 mM NaCl before
it was loaded into the calorimetry cell at concentrations of
75–100 lM with the addition of 1 mM DTT. Ligand solutions at
concentrations of 1 mM were dissolved in the same buffer and
typically injected between 0.5 lL and 2 lL at 150 s intervals with
stirring at 750 rpm. Buffer-ligand titrations were carried out as
reference runs and subtracted from the protein–ligand titration
to remove the heat of dilution. Data were analysed by fitting a
simple single-site model using Origin software (Microcal).
2.10. Enzymatic assays
ArgB activity was assessed by a colorimetric assay that followed
the release of ADP by measuring the oxidation of NADH at 340 nm,
for 30 min, in the presence of pyruvate kinase and lactate dehydro-
genase in a PHERAstar plate-reader (BMG-Labtech). The enzymatic
reactions (200 mL) were performed at 25 C and contained 50 mM
Tris pH 7.5, 200 mM NaCl, 50 mM KCl, 10 mM MgCl2, 0.3 mM
NADH, 2.5 mM phosphoenolpyruvate, 0.3 mM ATP, 1.25 mM N-a
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kinase/lactate dehydrogenase, 0.5 mMArgB, and varying concentra-
tions of inhibitors. Inhibitors were also individually screened
against the coupled enzymes to eliminate any compounds interfer-
ing with the other assay components. Competition assays were
performed in the same conditions using 0.3 mM of ATP or NAG
and varying the other substrate concentration.
To synthesise the ArgC substrate, a reaction mixture containing
3 lM ArgB, 1 mM NAG and 1 mM ATP in 50 mM Tris-HCl pH 7.5,
100 mM NaCl and 40 mM MgCl2 was made and the reaction was
allowed to proceed for 1–1.5 h at room temperature. Thereafter,
100 lL of the ArgC reaction mixture consisting of 50 mM Tris-
HCl pH 7.5, 100 mM NaCl and 0.6 mM NADPH (concentration in
200 lL), was added to each well together with 100 lL of the ArgB
reaction mixture and followed for 30 min at 35 C by measuring
the oxidation of NADPH at 340 nm. Controls with only NADPH,
2.5% DMSO (v/v) and no ArgC, as well as only NADPH, 4 mM frag-
ment and no ArgC were prepared. Baseline ArgC activity was
assayed with and without DMSO, the effect of 2.5% and 5% DMSO
on enzymatic activity was also tested. To test the inhibitory effect
of fragment binders identified from the crystallographic screening,
6 fragment concentrations (125 lM, 250 lM, 500 lM, 1 mM, 2 mM
and 4 mM,) were added to the reaction mixtures from suitable
DMSO stocks such that the final DMSO concentration was 2.5%.
All conditions were prepared in triplicates. 3.5 lM ArgC was added
just before measurements were started.
To assess the activity of ArgD an end point assay that follows
the reverse reaction of the enzyme was used in the presence and
absence of fragments. Reactions (100 lL) were set up containing
the following: 100 mM Tris-HCl pH 8, 3 mM N-acetylornithine
(NAO), 3.4 mM a-KG, 20 lM PLP and 4 lM enzyme. Duplicate reac-
tion mixtures were prepared for each time point and 8 time points
(0, 5, 10, 15, 20, 30, 45, 60 min) were tested in total. Two controls
were prepared: one with all reaction components except the
enzyme, and the other with all reaction components except NAO
(NAO was added after HCl treatment). The reactions tubes were
allowed to equilibrate in a heating block set at 37 C for two min-
utes, and the enzyme was added to initiate the reaction. After the
stipulated incubation times, contents of the reaction tubes were
quickly transferred to 1.5 ml microcentrifuge tubes containing
60 lL of 6 N HCl to stop the reactions. These tubes were then kept
in a heating block set at 95 C for 30 min, after which they were
cooled to 25 C in a water bath. 200 lL of 3.6 M sodium acetate
was added to each tube (final concentration of 1.8 M), along with
40 lL of 30 mM 2-aminobenzaldehyde (final concentration of
3 mM in a total volume of 400 lL). A yellow colouration started
developing as soon as the latter was added, the contents were vor-
texed and the tubes were incubated at 25 C for 15 min. 200 lL of
each reaction mixture was transferred into wells of a 96-well flat
bottom UV transparent microplate, and absorbance at 440 nm
was measured using the PHERAstar plate reader. All experiments
were performed at least in triplicate in a PHERAstar plate-reader
(BMG-Labtech) and the control without ArgD was used for blank
subtraction. Data were analysed with GraphPad Prism (Graphpad
Software). All reagents were obtained from Sigma-Aldrich.
2.11. M. tuberculosis culture condition and minimum inhibitory
concentration (MIC) determination
Mutant strain DargB and its complemented strain DargB-c were
generated before as mentioned [4] All the strains, wild type M.
tuberculosis H37Rv, mutant DargB and its complemented strain
DargB-c [4] as well as multidrug resistant (MDR) strain V2475
[36] were grown at 37 C to mid-log phase in Middlebrook 7H9
medium supplemented with 10% oleic acid-albumin-dextrose-
catalase (OADC), 0.5% glycerol, and 0.05% Tyloxapol supplemented3495with arginine (1 mM) washed and suspended in 7H9
media ± arginine (1 mM). For MIC, the cultures were diluted to
1/500 in ± arginine supplemented media. Serial two-fold dilutions
of each drug were prepared directly in a sterile 96-well plate using
0.1 ml of media with the appropriate supplement in the presence
or absence of 1 mM arginine. Same media with only vehicle (no
drug) was used as a control. PBS (0.2 ml) was added to all the
perimeter wells. The diluted M. tuberculosis strains in ± arginine
supplemented media (0.1 ml) were added to each well, and the
plate was incubated at 37 C for 7 days. Cell growth was measured
by optical density at 600 nm. An aqueous solution of resazurin
(0.2 mg/ml; 0.03 ml) was added to each well, and the plate was fur-
ther incubated for up to two days at 37 C. The MIC was deter-
mined as the lowest concentration at which the change of colour
from blue (resazurin) to pink (resorufin) did not occur.3. Results
3.1. DSF fragment screening
In the first stage of the screening, differential scanning fluo-
rimetry was used to screen an in-house library of 960 rule-of-
three compliant fragments against four enzymes of the arginine
biosynthesis pathway ArgB, ArgC, ArgD and ArgF. In the case of
ArgB, ArgC and ArgF the screening was performed against the
apoenzymes while for ArgD it was done with the PLP-bound form
since PLP binds covalently to the enzyme and it does not leave the
active site during catalysis. Several known ligands (substrates,
products, allosteric regulators and co-factors) were used as posi-
tive controls for each of the enzymes (Tables 1–4, Fig. S1). In all
cases, a fragment was considered a hit when the shift in melting
temperature was greater than five times the standard deviation.
3.1.1. ArgB
In the conditions used in the assay, ArgB with 5% DMSO (v/v)
displayed a melting temperature of 48 C. The addition of 1 mM
ATP, N-acetyl-glutamate and L-arginine showed positive melting
shifts of 2.0, 8.6 and 11.8 C respectively (Table 1, Fig. S1a). Of
the 960 compounds, a total of 63 (6.6%) showed a thermal shift
greater than five standard deviations (1.25 C) at 5 mM and were
considered hits. Out of those, 14 showed a large stabilization of
ArgB with a thermal shift greater than 5 C (Table 1) and were
selected for further validation.
3.1.2. ArgC
The apoenzyme ArgC with 5% DMSO (v/v) was found to have a
melting temperature of 67.7 C, while 1 mM NADP+ gave a small
average positive thermal shift of ~ 0.6 C and 1 mM NADPH pro-
duced an average negative thermal shift of 0.9 C across all DSF
runs performed (Table 2, Fig. S1b). 81 out of the 960 fragments
screened (8.5% of the library) at a concentration of 5 mM gave
a positive thermal shift greater than five standard deviations
(2.9 C). An orthogonal biophysical technique, Surface Plasmon
Resonance (SPR), was also employed to corroborate these hits
(Table 2).
3.1.3. ArgD
ArgD contains the prosthetic group PLP that does not leave the
active site of the enzyme. Therefore, all the PLP sites must remain
occupied during screening experiments to represent the native
state of the target. In an attempt to saturate all of the ArgD PLP
sites, PLP was added to ArgD during the purification of the protein.
Further confirmation was required to assess if most of the sites
were now saturated. To examine this, the melting profiles of unsat-
urated ArgD, saturated ArgD and the two forms in the presence
Table 1
ArgB validated fragment hits.
Compound Fragment structure DSF DTm (C) CPMG STD ITC Kd (mM)  IC50 (mM) #
NMR026 +7.6 binds binds ND ND
NMR043 +6.6 binds no binding ND ND
NMR078 +6.1 binds binds ND ND
NMR082 +7.0 binds binds ND ND
NMR314 +9.4 binds binds ND ND
NMR323 +5.4 binds binds ND ND
NMR446 +8.0 binds binds 24 ± 1.5 707 ± 7
NMR462 +6.0 binds no binding ND ND
NMR469 +10.5 binds binds ND ND
NMR582 +6.3 binds binds ND ND
NMR612 +5.3 binds no binding ND ND
NMR617 +6.4 binds no binding ND ND
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Table 1 (continued)
Compound Fragment structure DSF DTm (C) CPMG STD ITC Kd (mM)  IC50 (mM) #
NMR711 +7.9 binds binds 7.7 ± 0.8 366 ± 4
L-arginine +11.8 – – * 146 ± 1
NAG +8.6 – – 56 ± 5 –
ATP +2.0 – – ND –
L-canavanine +7.2 – – * 1460 ± 2
ND – not determined.
 – Attempts were made to determine the Kd for these ligands but without success.
* – L-arginine and L-canavanine ITC data could only be fitted with a sequential binding and the best fit was a six-site model with Kd of 4.5 ± 1.0, 4.8 ± 1.0, 6.1 ± 0.9, 9.4 ± 1.9,
12.9 ± 2.7 and 42 ± 8 mM for L-arginine and 4.5 ± 1.2, 4.8 ± 1.0, 6.4 ± 1.2, 34 ± 6.7, 35 ± 5.1 and 137 ± 26 mM for L-canavanine.
# - An inhibition % at 2.5 mM is given in Table S2 for compounds which an IC50 was not possible to obtain.
Table 2
ArgC validated fragment hits.
Compound compound structure DSF DTm (C) SPR Binding Response (RU) Binding site (X-ray) % inhibition at 2 mM
NMR322 +3.1 80.5 Substrate 45%
NMR401 +4.8 36.7 Co-factor 10%
NMR571 +3.1 78.0 Substrate 37%
NMR863 +5.0 41.6 Co-factor 12%
NADP +0.6 19.5 (1.25 mM) Co-factor –
NADPH 0.9 16.3 (1.25 mM) Co-factor –
Table 3
ArgD validated fragment hits.
Compound Fragment structure DSF DTm (C) SPR Binding Response with PLP injection (RU) % inhibition at 2 mM
NMR608 +2.4 50.3 16.6
NMR868 +0.9 ND ND
PLP +13 – –
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Table 4
ArgF validated fragment hits.
Compound Fragment structure DSF DTm
(C)
ITC
Kd (mM)
NMR007 3.0 161 ± 20
NMR078 4.5 ND
NMR288 3.5 ND
NMR464 4.1 ND
NMR502 3.5 ND
NMR801 3.1 ND
NMR812 3.6 120 ± 30
NMR817 3.1 ND
L-ornithine 1.5 ND
carbamoyl
phosphate
* *
L-citruline 1 ND
* – Carbamoyl phosphate is an unstable compound with and half-life time of 5
min at 37 C [43] and therefore a thermal shift and Kd for this molecule could not be
determined.
ND – not determined. Attempts were made to determine the Kd for these ligands
but without success.
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profile with 2 peaks, a large and broad peak with melting temper-
ature of 64.5 C, and a small peak with a melting temperature of
77 C (Fig. S1c). The addition of 1 mM PLP changed the melting pro-
file to a single peak with a melting temperature to 77.5 C
(Fig. S1c). ArgD that had PLP added during purification showed a
melting temperature of 77.5 C (Fig. S1c). The addition of 1 mM
PLP had now a very minor stabilizing effect shifting the melting
temperature to 79 C (Fig. S1c) and confirming that most PLP sites
were saturated. However, the protein in this state was insensitive
to fragment binding with maximum thermal shifts of 0.5 C being
observed. We therefore tested the potential of using the3498unsaturated protein for the screening. As mentioned above, PLP-
unsaturated ArgD exhibited a melting profile with 2 peaks, a large
and broad peak with melting temperature of 64.5 C (Fig. S1c),
likely a mixture of two different populations in which none or
one of the two protomers contain PLP, and a small peak with a
melting temperature of 77 C (Fig. S1c) which most likely corre-
sponded to a PLP-saturated population. The fact that the addition
of 1 mM PLP shifts the melting profile to a single peak with a melt-
ing temperature of 77.5 C corroborated this hypothesis.
Three different types of response in the melting profile to the
presence of fragments were observed while screening the PLP-
unsaturated ArgD (Fig. S1c). Most fragments showed either no
effect on the melting profile or a decrease in the melting tempera-
ture of the large peak or of both peaks and were discarded
(Fig. S1c). A second set caused a change in the melting profile with
a large increase in the intensity of the highest temperature peak
(Fig. S1c) suggesting that the fragment was preferentially binding
to the PLP binding site. The third set, had fragments that led to
an increase in melting temperature inferior to 4 C but maintained
the melting profile of the PLP-unsaturated ArgD control (Fig. S1c).
Fragments of this set could either be binding to the PLP site but not
stabilizing the protein sufficiently to show a clear change in the
melting profile, or could be binding elsewhere on the protein both
in the presence or absence of PLP. This set, represented by 47 frag-
ments (4.9% of the library) giving melting shifts of at least five
standard deviations (2 C) were therefore selected for SPR valida-
tion (Table 3).
3.1.4. ArgF
ArgF displayed a melting temperature of 63.5 C with 1 mM L-
ornithine and L-citrulline showing a positive melting shift of 1.5
and 1 C respectively. Of the 960 fragments, a total of 105
(10.9%) showed a thermal shift greater than five times standard
deviations (1.0 C) at 5 mM and were considered hits (Fig. S1d).
Out of these 16 displayed a melting shift greater than 3 C and
were selected for further validation by X-ray crystallography.
Due to the large number of hits for this protein, greater than 10%
of the whole library, a clustering analysis of the fragment hits
was performed. Centroids for each identified cluster and the repre-
sentative displaying the highest melting shift were also selected
for X-ray validation (Table 4).
3.2. Validation of DSF hits using a secondary screening technique
Three different strategies were employed to validate the hits
obtained with DSF. For ArgF, the fragment hits were taken directly
for X-ray crystallographic validation, for ArgB ligand-based NMR
was employed and for ArgC and ArgD SPR was performed to vali-
date the DSF hits.
3.2.1. ArgB
To validate the ArgB hits obtained by DSF, two ligand-based
NMR methods, Carr-Purcell-Meiboom-Gill (CPMG) and STD (satu-
rated transfer difference), were used [37,38] and fragments that
were validated by at least one method were considered as con-
firmed hits. CPMG experiments validated 15 out of the 16 frag-
ments while STD validated 11 out of 16. Only one fragment was
not validated by either of the methods and thus was not taken
forward.
3.2.2. ArgC and ArgD
ArgC and PLP-saturated ArgD were immobilised on an activated
carboxymethylated dextran surface via amine coupling and final
immobilisation response achieved was 16000 RU for ArgC and
7500 RU for ArgD (1000 RU roughly corresponding to 10 mg/
mL protein immobilised on the surface). For ArgD, a 1 mM PLP
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immobilisation response by 1100 RU. This was done to compen-
sate for loss of PLP in the low pH coupling buffer during immobil-
isation. The baseline throughout the screening experiment
remained at the post-PLP injection level (8570 RU), indicating
that PLP was not lost during the experiment.
The immobilised ArgC protein was tested first using dilution
series of NADPH and NADP+ (19 lM to 2.5 mM), and a clear dose
response suggested that predominantly, the enzyme had not been
immobilised in an orientation that occluded the active site. Simi-
larly, ArgD was tested using a dilution series of L-glutamate, N-
acetylornithine and L-ornithine (19 lM to 2.5 mM).
The fragment hits obtained previously were injected at a con-
centration of 1 mM. The sensorgrams for all the analytes were
inspected visually to exclude fragments with either no discernible
response or a ‘‘sticky” profile from further analysis (representative
sensorgrams for fragment binders are shown in Fig. S2a and b). The
binding level was calculated using the T200 software and adjusted
for molecular weights of the analytes (Fig. S2c and d). For ArgC, 22
fragments with a binding level response 20 RU were shortlisted,
whereas in the case of ArgD, 20 fragments with a response 10 RU
were shortlisted for crystallographic validation. Fragments were
thereafter described either as SPR ‘positive’ or ‘negative’.Fig. 2. (a) Overlap of X-ray crystal structures of protomers of Apo-ArgB, ArgB co-crysta
Structure of the ArgB hexamer with fragments bound at the interfacial site of two pro
interfacial site is highlighted in black dashed circles and the arginine binding site highligh
(c) and NMR446 (d). Hydrophobic interactions are depicted in green dots, weak hydroge
conformation is shown for clarity in both panels. [Fo - Fc] ‘‘Omit maps” of NMR711 (e) NM
the final model. The two adopted conformations are shown for both compounds. (For int
the web version of this article.)
34993.3. Crystallographic, biophysical and biochemical validation
The hits obtained for ArgB, ArgC, ArgD and ArgF were then
soaked in crystals of the respective protein and X-ray diffraction
data was collected. Data collection and refinement statistics for
all structures are available in Table S3.
3.3.1. ArgB
We obtained crystal structures for ArgB in the apo form and
with the natural ligands N-acetyl-glutamate (NAG) and L-
arginine (PDB: 7NLF, 7NLN, and 7NLO respectively) (Fig. 2a and
S3). L-canavanine, the guanidinooxy structural analogue of
L-arginine, was found to bind to the same site of ArgB as
L-arginine and induced conformational changes similar to those
induced by L-arginine (Fig. S4). The thirteen crystal structures of
ArgB with fragments in the absence of natural ligands show that
all the compounds were unexpectedly bound to a hydrophobic
cavity at the interface between two protomers with three of these
sites present in the ArgB hexamer (Fig. 2b-d, S3 and S5). This inter-
facial site is composed by the residues ala124, val125, gly126,
ile127, asp131, ala132, leu134, ala164, met165, leu168 and
arg173 and is mostly hydrophobic in nature (Fig. S6a). Due to the
nature of this new site, the interactions between the compoundsllised with N-acetyl glutamate (NAG), and ArgB co-crystallised with L-arginine. (b)
tomers and L-arginine overlayed. Each ArgB protomer is coloured differently. The
ted in red dashed circles. X-ray crystal structures of ArgB in complex with NMR711
n bonds in orange dots and carbon-p interactions in yellow disks. Only one binding
R446 (f) contoured at 1.5r. These maps were generated with using the phases from
erpretation of the references to colour in this figure legend, the reader is referred to
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and val125 interacting with NMR711 [2,8-bis(trifluoromethyl)-1H-
quinolin-4-one] (PDB: 7NNB) while for NMR446 [8-(trifluorome
thyl)-1H-quinolin-4-one] (PDB: 7NLX) ile127 is also involved in
the hydrophobic interactions (Fig. 2c and d). Carbon-p interactions
are also formed with leu168 for both compounds (Fig. 2c and d).
Finally, weak hydrogen bonds are also present between asp167,
leu168 and val125 for NMR711 while NMR446 interacts with
ile127 and leu168 via hydrophobic contacts (Fig. 2c and d). Fur-
thermore, this site is symmetrical and sits at a 2-fold crystallo-
graphic symmetry axis with each compound clearly presenting
two binding conformations (Fig. 2e, S3 and S5). Due to the 2-fold
symmetry of the site the two different binding conformations
likely represent the real interactions of each compound with the
protein with neither conformation being dominant. The two com-
pounds (NMR446 and NMR711) also share structural and binding
features with a trifluoromethyl group occupying the same position
at the binding site.
Enzymatic assays show that, of the 13 compounds, NMR711
and NMR446 were the best ArgB inhibitors, with an IC50 of 366
and 707 mM, respectively (Fig. 3a and Table 1). The natural allos-
teric regulator L-arginine and its analogue L-canavanine (Fig. 3a)
have IC50 values of 186 mM and 1.46 mM respectively. Additionally,
ITC experiments showed that compounds NMR711 and NMR446
bind to ArgB with a Kd of 7.7 and 23 mM, respectively (Table 1
and Fig. S7), whereas L-arginine and L-canavanine showed com-
plex binding curves that can only be fitted to a sequential binding
model showing a cooperative interaction with the different pro-
tomers of the hexamer (Table 1 and Fig. S7). NMR competition
assays revealed that compounds NMR711 and NMR446 are not
competitive with any of the natural ligands (ATP, NAG, and L-
arginine), with enzymatic assays also demonstrating the non-
competitive nature of ArgB inhibition by both fragments (Fig. S8).
This confirms that the results from X-ray crystal structures are
not an artefact and that the fragment-binding site is indeed a
new allosteric site. The observation that there are no conforma-
tional changes in the crystal structures of ArgB in any of theFig. 3. ArgB inhibition by arginine analogues and allosteric fragment inhibitors. (a) In
Lineweaver-burk plots for NMR711, NMR446, L-arginine and L-canavanine. Average of r
3500ArgB:fragment complex structures at the obtained resolutions
(2–2.5 Å) may be due to constraints arising from crystal packing.
Bioinformatics analysis showed that this site is conserved in
mycobacterial species and also in closely related actinobacteria,
such as Nocardia (Fig. S6b). Nevertheless, it is clear that binding
of these compounds, similar to L-arginine binding, causes changes
in the energy landscape of the protein that result in allosteric inhi-
bition of the catalytic reaction.
3.3.2. ArgC
Crystal structures were obtained for the ArgC apoenzyme (PDB:
7NNI) and the NADP+-bound holoenzyme (PDB: 7NNQ) (Fig. 4a).
Binding of NAPD+ causes significant structural changes in two
loops of the protein that move from a closed to open conformation
(Fig. 4a). Additionally, structures were solved with 4 fragment bin-
ders, occupying either of the two distinct pockets: the substrate-
binding (Fig. 4c and d) and the NADP(H)-binding pockets (Fig. 4e
and f). Fragments NMR322 (5-Methoxy-3-indoleacetic acid) and
NMR 571 (Xanthene-9-carboxylic acid) were observed in the
substrate-binding pocket (PDB: 7NOT and 7NNR respectively)
(Fig. 4c-d and S3). Both NMR322 and NMR571 engaged the side
chains of residues his217 and tyr211 through hydrogen bonds.
These two residues are predicted to stabilise the acyl-enzyme
intermediate during catalysis. NMR322 also made an H-bond inter-
action with ser186 and gly187. As compared to NMR571, NMR322
binds deeper in the pocket (Fig. 4c and d).
Fragments NMR401 (6-phenoxy-3-pyridinamine) and NMR863
(5-methoxy-1,3-benzoxazole-2-carboxylic acid) were observed in
the ribosylnicotinamide and pyrophosphate regions of the NADP
(H)-binding pockets (PDB: 7NPJ and 7NPH respectively) and the
majority of the interactions between the protein and these two
fragments are hydrophobic or p-interactions. Both fragments form
only a single hydrogen bond interaction with the thr325 side chain
in case of NMR401 (Fig. 4e and S3) and with the arg193 backbone
amine in the case of NMR863 (Fig. 4f and S3).
Enzymatic assays revealed that 2 mM NMR322 inhibited ArgC
activity by 45% whereas 2 mM NMR571 caused a 37% inhibition.hibition of ArgB activity by NMR711, NMR446, L-arginine and L-canavanine. (b)
eplicates and standard deviation are ploted (n = 3).
Fig. 4. (a) X-ray crystal structure of ArgC apoenzyme (green) superposed with the NAPD bound holoenzyme (white). (b) X-ray crystal structure of ArgC in complex with
NADP+. X-ray crystal structures of ArgC in complex with fragments NMR322 (c) and NMR571 (d) binding to the substrate site and NMR401 (e) and NMR863 (f) binding to the
co-factor site. Hydrogen bonds are represented by black dashed lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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NMR863 caused a 12% inhibition. Although the thermal shifts
obtained for NADP(H)-binding pocket fragments NMR401 and
NMR863 were higher than those for substrate-binding pocket
fragments NMR322 and NMR571, the SPR binding response for
the latter was better and positively correlated with percentage
inhibition of enzymatic activity (Table 2).
3.3.3. ArgD
The first crystal structure of the ArgD holoenzyme from M.
tuberculosis obtained (Fig. 5a) showed that the protomer has three
domains: the smaller N-terminal segment (residues 7 to 74), the
relatively larger C-terminal domain (residues 286 to 396), and
the central PLP-binding domain (residues 85 to 273), which is also
the largest and has a Rossmann-like overall fold (Fig. 5b and S3).
The prosthetic group PLP is covalently linked to lys253 via an aldi-
mine linkage. ArgD is a dimeric enzyme like other members of the
class III d-aminotransferase family [39]; the active sites are interfa-
cial, and residues of both protomers contribute to the active site
architecture (Fig. 5a) (PDB: 7NN1).
Fragment NMR608 (3-Hydroxy-2-naphthoic acid) was observed
occupying all four binding sites (4 chains in the ASU). It binds clo-
ser to the distal phosphate group of PLP than the proximal ring sys-
tem and the internal aldimine bond, where catalysis actually
occurs. However, it makes through its acid group, hydrogen bond
interactions with arg142, which could be the key residue involved3501in substrate binding based on homology with AstC, and with an
highly coordinated water through the hydroxyl group (Fig. 5c
and S3). While the pocket itself has depth, the fragment is more
solvent-exposed than the PLP molecule. Although NMR608 was
the only hit validated by all techniques, the fragment library con-
tained a compound with similar structure (NMR868), which had
only a melting shift of 0.9 C and therefore was not selected ini-
tially for further testing. However, soaking of this fragment
revealed that it binds in almost the same position as NMR608
(Fig. 5d and S3). Nevertheless, the orientation of the acid group is
slightly different for NMR868 and it no longer interacts directly
with arg142. In fact this fragment only has hydrogen bond interac-
tions with solvent molecules and it is only observed in one mole-
cule in the ASU out of four, most likely reflecting a lower affinity
(PDB: 7NNC).
Aminotransferases are often assayed for the reverse reactions
they catalyse because in most cases substrates for the forward
reaction are not commercially sold. The ArgD holoenzyme can also
use N-acetylornithine (NAO) and a-ketoglutarate (a-KG) to
generate N-acetyl-c-glutamyl-semialdehyde and glutamate. The
semialdehyde product spontaneously cyclises into D1-pyrroline-
5-carboxylic acid and can react with the reagent 2-amino-
benzaldehyde to yield a dihydroquinazolinium compound (bright
yellow colouration) that absorbs at 440 nm [40,41]. This assay
was employed to assess the effect of the fragment hits on ArgD.
NMR608 exhibited very weak activity with only 31% and 16%
Fig. 5. (a) X-ray crystal structure of M. tuberculosis ArgD showing the dimer. Each protomer of the dimer is highlighted in a different colour. The ArgD protomer comprises of
three domains shown in gold (N-terminal domain), green (PLP-binding a/b domain) and cyan (C-terminal domain) (b). X-ray crystal structures of ArgD in complex with
fragments NMR608 (c) and NMR868 (d). Each protomer of the dimer is highlighted in a different colour. Hydrogen bonds are represented by black dashed lines. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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with the crystal structures where the fragment is highly exposed to
the solvent.
3.3.4. ArgF
Crystal structures of apo ArgF and of ArgF in complex with the
natural ligand carbamoyl phosphate were initially obtained (PDB:
7NNF and 7NNV respectively). Carbamoyl phosphate interacts
with ArgF through hydrogen bonds with the side chains of ser50,
thr51, arg52, arg101, his128 and gln131 but also with the back-
bone amines of thr51, arg52 and thr53 and the carbonyl of
cys264 (Fig. 6a and S3). The residues ser50, thr51, arg52 are at
the N-terminus of a-helix 2 and the phosphate group of carbamoyl
phosphate sit at the positive pole of the helix. Binding of carbamoyl
phosphate to ArgF slightly displaces a-helix 2 when compared to
the apo structure (Fig. S9a). Soaking ArgF with fragment hits
yielded eight crystals structures. All fragments occupied a site at
the interface between two protomers of the ArgF trimer but not
all sites are equally occupied by all fragments (Fig. 6b-e and S9b-
f). This site contacts directly with the a-helix 2 and sits between
this helix and a-helix 3 of the opposing protomer. The site is
formed by residues thr51, arg52, phe55 of a-helix 2, leu265,
ala289, arg292 of protomer 1 and ile45, ser75, thr76, leu78,
glu82, thr87, leu91 and tyr94 of protomer 2. These residues form
a cavity that opens to the carbamoyl phosphate binding site. Bind-
ing of fragments at this site, shifts the position of a-helix 2 by 1.9 Å,3502when compared to the carbamoyl phosphate structure, and also
affects the conformation of arg52 which is involved in carbamoyl
phosphate binding. Fragments were found to bind in two distinct
sub sites across the main binding site and could be divided in three
different groups based on their mode of binding. NMR007, 078, 464
and 502 occupied the top area of the site (subsite 1) and contacted
with a loop of protomer 2 that is composed by residues asp72 to
leu84 that covers the site (Fig. 6c and S9b-d). NMR801, the single
representative of this group sits at the bottom of the site (subsite
2) between a-helix 2 of protomer 1 and a-helix 3 of the opposing
protomer (Fig. 6d). NMR288, 812 and 817 have two molecules
binding at this site, with one molecule occupying each subsite
(Fig. 4E and S2E-F). All fragments keep a-helix 2 in a position close
to the apo structure or move further away from the position this
helix occupies when carbamoyl phosphate is bound, albeit very
slightly. A Kd value could only be determined for NMR007 and
NMR812 and both fragments showed affinities worse than
100 mM (Table 4 and Fig. S10).3.4. Effect of ArgB inhibitors in M. tuberculosis growth
Considering the four enzymes of the arginine biosynthesis path-
way screened, ArgB hits exhibited higher potency by far, with
NMR711 and NMR446 being selected to assess their effect on M.
tuberculosis together with L-canavanine.
Fig. 6. (a) X-ray crystal structure of M. tuberculosis ArgF in complex with carbamoyl phosphate. Hydrogen bonds are depicted as black dashed lines. Two of the protomers of
the trimer are visible and are coloured differently. (b) Structure of the ArgF trimer bound with fragments NMR007 (yellow), NMR801 (purple) and NMR812 (white) at
interfacial site. Three X-ray crystal structure of ArgF in complex with different fragments were superposed with the apo structure to create this figure. X-ray crystal structures
of ArgF in complex with NMR007, representing the group that binds to subsite 1 (c), in complex with NMR801, the single representative of the group that binds to subsite 2
(d) and in complex with NMR812, representing the group of fragments that bind to both subsites (e). Hydrogen bonds are depicted as black dashed lines. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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was examined by measuring their minimum inhibitory concentra-
tions (MICs) in the absence or presence of arginine (1 mM). All the
compounds inhibited the growth of M. tuberculosis H37Rv, DargB-c
as well as MDR strain V2475 in media without arginine compared
to no drug control (Figs. 7 and 8). MICs for NMR711, NMR446 and
L-canavanine were 25–50, >200 and 50 mg/ml against H37Rv,
DargB-c and 25–50, >200, >200 mg/ml against V2475 (Figs. 7 and
8). However, when arginine (1 mM) was present in the media,
compound NMR446 and L-canavanine had no inhibitory activity
against H37Rv, DargB-c and, DargB. This indicates that these com-
pounds are indeed specifically inhibiting M. tuberculosis arginine
biosynthesis (Fig. 7). In contrast, the more promiscuous NMR711
was inhibitory for all the above strains in the presence or absence
of arginine, suggesting that NMR711 may target additional pro-
teins (Figs. 7 and 8).
Using the FBDD approach, we have discovered inhibitors that
bind to a new allosteric site in ArgB, which has very different prop-
erties than that of the active site and L-arginine binding sites, thus
opening new possibilities for drug discovery by targeting ArgB. For
fragment-sized molecules, both compounds reported in this work
bind tightly and allosterically to ArgB and have growth inhibitory
activity against M. tuberculosis, suggesting that they have the
potential to provide a framework for developing larger and higher
affinity molecules against the ArgB protein.35034. Discussion
The arginine biosynthesis pathway has been established as a
good target for anti-TB drug discovery [4,14]. Arginine deprivation
in M. tuberculosis induced by knocking out argB and argF results in
both in vitro and in vivo sterilisation of M. tuberculosis, without the
emergence of suppressor mutants [4]. However, from a pathway
with eight enzymes, only ArgJ has been explored in a drug discov-
ery campaign and all other enzymes of the pathway, prior to this
work, were yet to be assessed in their potential as suitable targets
for drug discovery.
Fragments are potent chemical tools that can efficaciously
explore the surface of proteins for new binding sites and their
chemical space, even with small libraries of a few hundreds of
compounds and can consequently be employed to assess the
ligandability of protein targets [18,42]. Therefore, this approach
was employed to assess the ligandability of ArgB, ArgC, ArgD and
ArgF, and to identify potential starting points for fragment
elaboration.
We have screened a fragment library of 960 small compounds
(MW 150–300 Da) initially using DSF and subsequently employed
ligand-based NMR, SPR, ITC, biochemical assays and X-ray crystal-
lography to validate the DSF hits. Due to the nature of FBDD, a hit
is only considered validated when an X-ray crystal structure is
obtained. For all the proteins in this work, hits were identified
Fig. 7. Dose response curves of inhibitor compounds for inhibition of M. tuberculosis growth (measured as optical density at 600 nm) in the presence (a-c) or in the absence
(d-e) of 1 mM L-arginine. Data are represented as percentage growth ofM. tuberculosis strains in the presence of different concentrations of the inhibitor compared to growth
in the presence of just vehicle control (no drug). H37Rv (a,d), complemented DargB (DargB-c; b,e), and DargB (c). Data are representative of one of three independent
experiments. Error bars, mean s.d. (n = 3). NMR711 (green circles), NMR446 (red circles) and L-Canavanine (blue circle). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
P. Gupta, S.E. Thomas, S.A. Zaidan et al. Computational and Structural Biotechnology Journal 19 (2021) 3491–3506and eventually validated by X-ray crystallography. ArgB had the
highest number of X-ray validated hits with a total of thirteen,
followed by ArgF with eight, ArgC with four and ArgD with
two. Interestingly, in the case of ArgB and ArgF, all the fragment
hits were binding to an interfacial site, which in the case of ArgB
was confirmed to have functional implications. In the case of
ArgF, its close proximity to the active site shows potential to
develop compounds that can anchor at the interfacial site and
then extend towards the active site to interfere with catalysis.
Similarly for ArgJ, the only enzyme of the pathway with known
inhibitors prior to this work, the inhibitors were also found to
bind to an interfacial allosteric site [14]. Our results further show
that in the case of ArgC there are two possible strategies to
develop inhibitors, with one targeting the cofactor binding site
and the other the substrate binding site. It is not clear at this
point which strategy has the highest potential to result in potent
inhibitors. Another consideration to take into account is the
extent of homology of these enzymes with the human orthologue.
While ArgB and ArgC do not have a human orthologue, ArgD and
ArgF do and the M. tuberculosis enzymes have identities of 36 and
41% with the human orthologues, respectively. Nevertheless,
while the ArgF active site is conserved, the interfacial site of ArgF
contains several differences which can be exploited for develop-
ing specific inhibitors for the M. tuberculosis enzyme. For ArgD
selectivity might be more difficult to achieve since many of the
active site residues are conserved in comparison with the human
cytoplasmic and mitochondrial enzymes.
Due to the potency of the best fragments against ArgB, we
tested them for their ability to inhibit M. tuberculosis growth3504together with L-canavanine. Remarkably, NMR446 and L-
canavanine not only inhibitedM. tuberculosis growth, but were also
found to act on-target despite the potential promiscuity of such
small compounds, with both becoming inactive after the addition
of L-arginine to the media.
Despite these promising results, the interfacial site of ArgB
might be the hardest of all sites found in this study to develop
small molecule inhibitors. The intrinsic highly hydrophobic nature
of the site together with very few opportunities to engage in
hydrogen bonds and other polar contacts creates difficulties in
rationalising what modifications could improve the potency of
the compounds. Furthermore, the fact that we cannot observe con-
formational changes in any of the structures with fragments bound
to ArgB may be due to constraints arising from crystal packing and
thus these structures may not completely represent what occurs in
solution. It is however also possible that binding to this site does
not cause visible conformational changes but still alters the energy
landscape of the intramolecular pathways involved in the catalytic
cycle. We cannot currently determine which of these two hypothe-
ses is correct.
In conclusion, by using a fragment-based approach, we have
discovered inhibitors that bind to novel sites in ArgB and ArgF
and to the active sites of ArgC and ArgD, which in case of ArgB
show on target activity against M. tuberculosis. The data pre-
sented here clearly demonstrates the potentiality and scope to
target enzymes in the de novo arginine biosynthesis of M. tuber-
culosis with dedicated drug discovery programs and we propose
ArgC and ArgF as the best candidates for future drug discovery
work.
Fig. 8. Inhibition of growth of M. tuberculosis MDR strain V2475 by inhibitor sin the
dose dependent manner in the presence (a) or in the absence (b) of 1 mM L-
arginine. Data is represented as percentage growth of V2475 in the presence of
different concentrations of the inhibitor compared to growth in the presence of just
vehicle control (no drug). Data is representative of one of the three independent
experiments. Error bars, mean s.d. (n = 3). NMR711 (green circles), NMR446 (red
circles) and L-Canavanine (blue circle). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
P. Gupta, S.E. Thomas, S.A. Zaidan et al. Computational and Structural Biotechnology Journal 19 (2021) 3491–3506Author contributions
VM and ST conceived the work. VM, PG and ST wrote the manu-
script with contributions of TLB and WRJ Jr. VM, SET, PG, JCW, EC
and CM cloned and purified the proteins. VM, PG, SET, JCW, VSP,
AB, EC and CM performed the fragment screening, biophysical val-
idation and biochemical assays. VM, PG, JCW, AB, EC and CM crys-
tallised the proteins, collected crystallographic data and refined
the structures. ST, SAZ and MAP performed the experiments with
M. tuberculosis. AGC and CA contributed with the fragment library.
All authors approved the manuscript.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
Acknowledgements
This work was funded by Bill and Melinda Gates Foundation
HIT-TB (OPP1024021) and SHORTEN-TB (OPP1158806). PG was
funded by a Gates Cambridge Scholarship. TLB is funded by the
Wellcome Trust (Wellcome Trust Investigator Award3505200814_Z_16_Z: RG83114). ST acknowledges SC1GM140968 grant
from National Institute of Health to support this work. The authors
would like to thank the Diamond Light Source and ESRF for beam-
time (proposals mx14043, mx18548 for Diamond Light Source and
MX2078 for ESRF).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.csbj.2021.06.006.
References
[1] World Health O. Global tuberculosis report 2019. Geneva: World Health
Organization; 2019.
[2] Vilchèze C, Jacobs WR. The isoniazid paradigm of killing, resistance, and
persistence in Mycobacterium tuberculosis. J Mol Biol 2019;431(18):3450–61.
[3] Berney M, Berney-Meyer L, Wong K-W, Chen B, Chen M, Kim J, et al. Essential
roles of methionine and S-adenosylmethionine in the autarkic lifestyle of
Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2015;112
(32):10008–13.
[4] Tiwari S, van Tonder AJ, Vilchèze C, Mendes V, Thomas SE, Malek A, et al.
Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium
tuberculosis. Proc Natl Acad Sci U S A 2018;115(39):9779–84. https://doi.
org/10.1073/pnas.1808874115.
[5] Gouzy A, Poquet Y, Neyrolles O. Nitrogen metabolism in Mycobacterium
tuberculosis physiology and virulence. Nat Rev Microbiol 2014;12
(11):729–37.
[6] Zhang YJ, Rubin EJ. Feast or famine: the host-pathogen battle over amino acids.
Cell Microbiol 2013;15(7):1079–87.
[7] Lee S, Jeon B-Y, Bardarov S, Chen M, Morris SL, Jacobs WR. Protection elicited
by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo
growth phenotypes of the four unique glutamine synthetase mutants in a
murine model. Infect Immun 2006;74(11):6491–5.
[8] Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, et al.
A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated
and protects mice against tuberculosis. Nat Med 2002;8(10):1171–4.
[9] Clements JD, Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of
auxotrophic mutants of Mycobacterium tuberculosis and their potential as
vaccine candidates. Infect Immun 2001;69(2):1142–50.
[10] Tuomanen EI, Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, et al.
Attenuation of and protection induced by a leucine auxotroph of
Mycobacterium tuberculosis. Infect Immun 2000;68(5):2888–98.
[11] Peteroy-Kelly MA, Venketaraman V, Talaue M, Seth A, Connell ND. Modulation
of J774.1 macrophage L-arginine metabolism by intracellular Mycobacterium
bovis BCG. Infect Immun 2003;71:1011–5.
[12] Seth A, Connell ND. Amino acid transport and metabolism in mycobacteria:
cloning, interruption, and characterization of an L-Arginine/gamma-
aminobutyric acid permease in Mycobacterium bovis BCG. J Bacteriol
2000;182:919–27.
[13] Kaufmann SHE, Gobert AP, Daulouede S, Lepoivre M, Boucher JL, Bouteille B,
et al. L-Arginine availability modulates local nitric oxide production and
parasite killing in experimental trypanosomiasis. Infect Immun 2000;68
(8):4653–7.
[14] Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A. 2018. An allosteric
inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel
combinatorial therapy. EMBO Mol Med 10.
[15] DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, Rubin EJ,
Schnappinger D, Ehrt S, Fortune SM, Sassetti CM, Ioerger TR. 2017.
Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis
Genome via Saturating Transposon Mutagenesis. MBio 8.
[16] Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the
impact of fragments on drug discovery. Nat Rev Drug Discov 2016;15
(9):605–19.
[17] ThomasSE,CollinsP,JamesRH,MendesV,CharoensutthivarakulS,RadouxC,etal.
Structure-guided fragment-based drug discovery at the synchrotron: screening
binding sites and correlations with hotspot mapping. Philos Trans A Math Phys
Eng Sci 2019;377(2147):20180422. https://doi.org/10.1098/rsta.2018.0422.
[18] Mendes V, Blundell TL. Targeting tuberculosis using structure-guided
fragment-based drug design. Drug Discov Today 2017;22(3):546–54.
[19] Thomas SE, Whitehouse AJ, Brown K, Burbaud S, Belardinelli JM, Sangen J,
Lahiri R, Libardo MDJ, Gupta P, Malhotra S, Boshoff HIM, Jackson M, Abell C,
Coyne AG, Blundell TL, Floto RA, Mendes V. 2020. Fragment-based discovery of
a new class of inhibitors targeting mycobacterial tRNA modification. Nucl
Acids Res 48:8099-8112.
[20] Sabbah M, Mendes V, Vistal RG, Dias DMG, Záhorszká M, Mikušová K, et al.
Fragment-based design of Mycobacterium tuberculosis InhA inhibitors. J Med
Chem 2020;63(9):4749–61.
[21] Whitehouse AJ, Thomas SE, Brown KP, Fanourakis A, Chan D-H, Libardo MDJ,
et al. Development of Inhibitors against Mycobacterium abscessus tRNA (m(1)
G37) Methyltransferase (TrmD) Using Fragment-Based Approaches. J Med
Chem 2019;62(15):7210–32.
P. Gupta, S.E. Thomas, S.A. Zaidan et al. Computational and Structural Biotechnology Journal 19 (2021) 3491–3506[22] Villemagne B, Machelart A, Tran NC, Flipo M, Moune M, Leroux F, et al.
Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting
activity. ACS Infect Dis 2020;6(3):366–78.
[23] Prati F, Zuccotto F, Fletcher D, Convery MA, Fernandez-Menendez R, Bates R,
et al. Screening of a novel fragment library with functional complexity against
Mycobacterium tuberculosis InhA. ChemMedChem 2018;13(7):672–7.
[24] Villemagne B, Flipo M, Blondiaux N, Crauste C, Malaquin S, Leroux F, et al.
Ligand efficiency driven design of new inhibitors of Mycobacterium
tuberculosis transcriptional repressor EthR using fragment growing,
merging, and linking approaches. J Med Chem 2014;57(11):4876–88.
[25] Ribeiro JA, Hammer A, Libreros-Zúñiga GA, Chavez-Pacheco SM, Tyrakis P, de
Oliveira GS, et al. Using a Fragment-Based Approach to Identify Alternative
Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium
tuberculosis. ACS Infect Dis 2020;6(8):2192–201.
[26] Faïon L, Djaout K, Frita R, Pintiala C, Cantrelle F-X, Moune M, et al. Discovery of
the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a
fragment-based screening. Eur J Med Chem 2020;200:112440. https://doi.org/
10.1016/j.ejmech.2020.112440.
[27] Peranen J, Rikkonen M, Hyvonen M, Kaariainen L. T7 vectors with modified
T7lac promoter for expression of proteins in Escherichia coli. Anal Biochem
1996;236:371–3.
[28] Mendes V, Acebron-Garcia-de-Eulate M, Verma N, Blaszczyk M, Dias MVB,
Blundell TL. 2019. Mycobacterial OtsA Structures Unveil Substrate Preference
Mechanism and Allosteric Regulation by 2-Oxoglutarate and 2-
Phosphoglycerate. mBio 10.
[29] Cherney LT, Cherney MM, Garen CR, Niu C, Moradian F, James MN. Crystal
structure of N-acetyl-gamma-glutamyl-phosphate reductase from
Mycobacterium tuberculosis in complex with NADP(+). J Mol Biol
2007;367:1357–69.
[30] Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, et al. Data
processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol
Crystallogr 2011;67(4):293–302.
[31] Winter G. xia2: an expert system for macromolecular crystallography data
reduction. J Appl Crystallogr 2010;43(1):186–90.
[32] McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.
Phaser crystallographic software. J Appl Crystallogr 2007;40(4):658–74.3506[33] Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX:
a comprehensive Python-based system for macromolecular structure solution.
Acta Crystallogr D Biol Crystallogr 2010;66(2):213–21.
[34] Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot.
Acta Crystallogr D Biol Crystallogr 2010;66(4):486–501.
[35] Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW,
Mustyakimov M, et al. Towards automated crystallographic structure
refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 2012;68
(4):352–67.
[36] Ioerger TR, Koo S, No EG, Chen X, Larsen MH, Jacobs WR, Jr., Pillay M, Sturm
AW, Sacchettini JC. 2009. Genome analysis of multi- and extensively-drug-
resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 4:e7778.
[37] Mayer M, Meyer B. Characterization of ligand binding by saturation transfer
difference NMR spectroscopy. Angew Chem Int Ed Engl 1999;38(12):1784–8.
[38] Loria JP, Rance M, Palmer AG. A relaxation-compensated
CarrPurcellMeiboomGill sequence for characterizing chemical exchange
by NMR spectroscopy. J Am Chem Soc 1999;121(10):2331–2.
[39] Newman J, Seabrook S, Surjadi R, Williams CC, Lucent D, Wilding M, Scott C,
Peat TS. 2013. Determination of the structure of the catabolic N-
succinylornithine transaminase (AstC) from Escherichia coli. PLoS One 8:
e58298.
[40] Vogel HJ, Davis BD. Glutamic c-semialdehyde and d1-pyrroline-5-carboxylic
acid, intermediates in the biosynthesis of proline 1,2. J Am Chem Soc 1952;74
(1):109–12.
[41] Albrecht AM, Vogel HJ. Acetylornithine Delta-transaminase. Partial
purification and repression behavior. J Biol Chem 1964;239:1872–6.
[42] Canning P, Birchall K, Kettleborough CA, Merritt A, Coombs PJ. Fragment-based
target screening as an empirical approach to prioritising targets: a case study
on antibacterials. Drug Discov Today 2020;25(11):2030–7. https://doi.org/
10.1016/j.drudis.2020.09.003.
[43] Wang Q, Xia J, Guallar V, Krilov G, Kantrowitz ER. Mechanism of thermal
decomposition of carbamoyl phosphate and its stabilization by aspartate and
ornithine transcarbamoylases. Proc Natl Acad Sci U S A 2008;105
(44):16918–23.
